16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A high-throughput lysosome trafficking assay guides ligand selection and elucidates differences in CD22-targeted nanodelivery

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Targeted nanoparticles offer potential to selectively deliver therapeutics to cells; however, their subcellular fate following endocytosis must be understood to properly design mechanisms of drug release. Here we describe a nanoparticle platform and associated cell-based assay to observe lysosome trafficking of targeted nanoparticles in live cells. The nanoparticle platform utilizes two fluorescent dyes loaded onto PEG-poly(glutamic acid) and PEG-poly(Lysine) block co-polymers that also comprise azide reactive handles on PEG termini to attach antibody-based targeting ligands. Fluorophores were selected to be pH-sensitive (pHrodo Red) or pH-insensitive (Alexafluor 488) to report when nanoparticles enter low pH lysosomes. Dye-labelled block co-polymers were further assembled into polyion complex micelle nanoparticles and crosslinked through amide bond formation to form stable nano-scaffolds for ligand attachment. Cell binding and lysosome trafficking was determined in live cells by fluorescence imaging in 96-well plates and quantification of red- and green-fluorescence signals over time. The platform and assay was validated for selection of optimal antibody-derived targeting ligands directed towards CD22 for nanoparticle delivery. Kinetic analysis of uptake and lysosome trafficking indicated differences between ligand types and the ligand with the highest lysosome trafficking efficiency translated into effective DNA delivery with nanoparticles bearing the optimal ligand.

          GRAPHICAL ABSTRACT

          IMPACT STATEMENT

          The ability of this pH-sensitive reporter platform to rapidly screen ligands in nanoparticle format will enable identification and production of targeted NPs with desired lysosome trafficking properties.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: not found

          Engineering precision nanoparticles for drug delivery

          In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Applying systems-level spectral imaging and analysis to reveal the organelle interactome

            The organization of the eukaryotic cell into discrete membrane-bound organelles allows for the separation of incompatible biochemical processes, yet the activities of these organelles must be coordinated. For example, lipid metabolism is distributed between the endoplasmic reticulum (ER) for lipid synthesis, lipid droplets (LDs) for storage and transport, mitochondria and peroxisomes for β-oxidation, and lysosomes for lipid hydrolysis and recycling 1–5 . Organelle contacts are increasingly understood to be vital for diverse cellular functions 5–8 . However, the spatial and temporal organization of organelles within the cell remains poorly characterized due to the inability of fluorescence imaging-based approaches to distinguish more than a few fluorescent labels in a single image 9 . Here we present a systems-level analysis of the organelle interactome using a multispectral image acquisition method that overcomes the challenge of spectral overlap in the fluorescent protein palette. We employed confocal and lattice light sheet (LLS) 10 instrumentation and an imaging informatics pipeline of five steps to achieve mapping of organelle numbers/volumes/speeds/positions and dynamic inter-organelle contacts in live fibroblast cells. We describe the frequency and locality of two-, three-, four-, and five-way interactions among six different membrane-bound organelles (ER, Golgi, lysosome, peroxisome, mitochondria and LD) and show how these relationships change over time. We demonstrate that each organelle has a characteristic distribution and dispersion pattern in three-dimensional space and that there is a reproducible pattern of contacts among the six organelles, impacted by microtubule and cell nutrient status. These live-cell confocal and LLS spectral-imaging approaches are applicable to any cell system expressing multiple fluorescent probes, whether in normal conditions or when cells are exposed to disturbances such as drugs, pathogens or stress. This methodology thus offers a powerful new descriptive tool and source for hypotheses about cellular organization and dynamics.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion.

              Autophagosome-lysosome fusion and autolysosome acidification constitute late steps in the autophagic process necessary to maintain functional autophagic flux and cellular homeostasis. Both of these steps are disrupted by the V-ATPase inhibitor bafilomycin A1, but the mechanisms potentially linking them are unclear. We recently revisited the role of lysosomal acidification in autophagosome-lysosome fusion, using an in vivo approach in Drosophila. By genetically depleting individual subunits of the V-ATPase, we confirmed its role in lysosomal acidification and autophagic cargo degradation. Surprisingly, vesicle fusion remained active in V-ATPase-depleted cells, indicating that autophagosome-lysosome fusion and autolysosome acidification are 2 separable processes. In contrast, bafilomycin A1 inhibited both acidification and fusion, consistent with its effects in mammalian cells. Together, these results imply that this drug inhibits fusion independently of its effect on V-ATPase-mediated acidification. We identified the ER-calcium ATPase Ca-P60A/dSERCA as a novel target of bafilomycin A1. Autophagosome-lysosome fusion was defective in Ca-P60A/dSERCA-depleted cells, and bafilomycin A1 induced a significant increase in cytosolic calcium concentration and disrupted Ca-P60A/SERCA-mediated fusion. Thus, bafilomycin A1 disrupts autophagic flux by independently inhibiting V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion.
                Bookmark

                Author and article information

                Journal
                Sci Technol Adv Mater
                Sci Technol Adv Mater
                Science and Technology of Advanced Materials
                Taylor & Francis
                1468-6996
                1878-5514
                13 May 2024
                2024
                13 May 2024
                : 25
                : 1
                : 2351791
                Affiliations
                [a ]Biologics Engineering, Oncology R&D, AstraZeneca; , Gaithersburg, MD, USA
                [b ]Discovery Sciences, BioPharma R&D, AstraZeneca; , Gaithersburg, MD, USA
                Author notes
                CONTACT Hannah J. Vaughan hannah.vaughan@ 123456astrazeneca.com Biologics Engineering, Oncology R&D, AstraZeneca Pharmaceuticals, LP., One MedImmune Way, Gaithersburg, MD 20901, USA
                Article
                2351791
                10.1080/14686996.2024.2351791
                11138227
                38817250
                27474c22-fc6f-4f19-b501-263bf3fd2bee
                © 2024 AstraZeneca. Published by National Institute for Materials Science in partnership with Taylor & Francis Group.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

                History
                Page count
                Figures: 7, References: 69, Pages: 1
                Categories
                Research Article
                Bio-Inspired and Biomedical Materials

                targeted delivery,nanoparticles,biomaterials,subcellular trafficking,high-throughput assay,nucleic acid

                Comments

                Comment on this article